Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Z. Ballatore(Marche Polytechnic University), Daniele Generali(University of Trieste), Alberto Zambelli, Maria Giuseppina Sarobba, Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Alessandra Fabi(Agostino Gemelli University Polyclinic), Donatella Grasso(Novartis (Italy)), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Simon Spazzapan(Centro di Riferimento Oncologico), Antonella Ferro(Ospedale Santa Chiara), Luigi Coltelli(Ospedale di Livorno), Alberto Ballestrero(Ospedale Policlinico San Martino), Andrea Michelotti(University of Pisa), Riccardo Masetti(Agostino Gemelli University Polyclinic), Manuelita Mazza, Rosalba Torrisi(IRCCS Humanitas Research Hospital), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 3
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684